Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T12:01:38.996Z.
Calculation as of: 2026-10-06T12:01:38.996Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 003104a745df447911be4c5a9e680832c7b19445192e606e8359fbce1df4db86
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$1.02M
EV/Sales Ratio
N/A
TTM Avg
26520.58x
3Y Avg
26520.58x
5Y Avg
26520.58x
Market Cap
$888387.00
EV/Sales Ratio
N/A
TTM Avg
78.84x
3Y Avg
47.25x
5Y Avg
902.93x
Market Cap
$885939.00
EV/Sales Ratio
N/A
TTM Avg
48327.79x
3Y Avg
43699.06x
5Y Avg
43699.06x
Market Cap
$878396.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$787624.00
EV/Sales Ratio
N/A
TTM Avg
2170.65x
3Y Avg
2189.01x
5Y Avg
2189.01x
Market Cap
$1.49M
EV/Sales Ratio
N/A
TTM Avg
0.01x
3Y Avg
35696307.79x
5Y Avg
35696307.79x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clearmind Medicine Inc. (CMND) | $1.11M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A | 26520.58x | 26520.58x | 26520.58x |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | N/A | 78.84x | 47.25x | 902.93x |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | N/A | 48327.79x | 43699.06x | 43699.06x |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | N/A | 2170.65x | 2189.01x | 2189.01x |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | N/A | 0.01x | 35696307.79x | 35696307.79x |
| CDT Equity Inc. (CDT)vs › | $707297.00 | 0.67x | 1.27x | 1.27x | 1.27x |
| Curis, Inc. (CRIS)vs › | $1.54M | N/A | 0.94x | 2.21x | 9.57x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
